Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03883724
Other study ID # PRO18100572
Secondary ID R21AG060292
Status Completed
Phase N/A
First received
Last updated
Start date February 1, 2019
Est. completion date November 30, 2021

Study information

Verified date November 2022
Source University of Pittsburgh
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Nocturia is prevalent in older adults and it vastly reduces quality of life. Yet its treatment remains inadequate because its causes are not well understood, especially nocturnal polyuria or increased urine production at night. This study, which builds on the investigators' ongoing research, would be the first of its kind to explore the role of sleep in nighttime urine production. The findings will contribute important knowledge to guide development of better targeted and more effective therapy for this prevalent and morbid condition.


Description:

Prevalent, morbid, and costly ($61 billion/year in 2012), nocturia is a major problem, especially for older adults. It increases the risk of falls, fractures, depression, nursing home placement, and death. Yet management of nocturia remains inadequate. Most behavior and pharmacotherapies for nocturia focus on bladder-related etiologies, and it's most prevalent attribute nocturnal polyuria (NP), or increased urine production during sleep remains poorly understood and inadequately treated with little advancement over the last 50 years. Disruption of diurnal excretory pattern, with higher nighttime urine production is common in older adults. While studies in young adults show that sleep plays a critical role in regulating nighttime urine production, among older adults the role of poor sleep in NP is under-investigated. Urine production follows a circadian pattern in which transition from wake to sleep is followed by a pronounced decrease in excretion of water, electrolytes and other osmotically active substances. Studies in young population have established that physiological urine production follows a circadian rhythm, which is regulated by diurnal variation in secretion of hormones controlling water and salt excretion such as arginine vasopressin, renin-angiotensin-aldosterone system, and atrial natriuretic peptide. Sleep deprivation blunts nocturnal surge of these hormones and consequently alter water and salt excretion thereby increase nighttime urine volume leading to NP. Recent evidence suggests that poor sleep quality, frequent sleep interruptions especially in the first part of the night and shorter duration of first uninterrupted sleep period are associated with NP but its pathophysiology is not fully understood. Additionally, among older adults with poor sleep, the investigators have shown that a behavioral intervention directed solely towards sleep (BBTI- brief behavioral treatment of insomnia an efficacious multimodal behavioral treatment for insomnia) not only improves sleep, but also nocturia. Hence, the investigators postulate that sleep interruptions in the first part of the sleep impacts the hormonal regulation of nighttime urine production causing NP. In addition, the investigators postulate that interventions to prolong the first uninterrupted sleep period will decrease NP and hence nocturia. The, aims of the present proposal are to: 1) examine the impact of BBTI on duration of the first of uninterrupted sleep period and NP in elderly with nocturia; and 2) establish NP and duration of first uninterrupted sleep as mechanisms by which BBTI impacts nocturia. The investigators' hypothesis is that BBTI improves nocturia not only by improving sleep, (and specifically, duration of the first uninterrupted sleep period), but also by decreasing NP. To accomplish these goals the investigators will recruit 60 community dwelling adults (aged >65) with nocturia and NP. Sleep will be assessed subjectively with the Insomnia Severity Index and objectively by 7-day sleep diary and wrist actigraph. Concurrently the investigators will collect 3-day bladder diary data to document their voiding pattern and volume during day and night. Participants will be randomized to receive the 4-week behavioral sleep intervention BBTI by a trained therapist or an information control intervention. The participants will repeat the study measures post-intervention. The study results will provide important insights into shared pathological mechanisms underlying poor sleep, nocturia and nighttime urine production.


Recruitment information / eligibility

Status Completed
Enrollment 56
Est. completion date November 30, 2021
Est. primary completion date November 30, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: - ambulatory and functionally-independent community-dwelling men and women - aged 65 years, or more - with nocturia =2/night - poor sleep because of frequent awakenings Exclusion Criteria: - Unstable or acute medical or central nervous system conditions - Untreated, current, severe psychiatric condition - Untreated, current, severe overactive bladder syndrome - Post void residual > 30ml - Sleep apnea with AHI=15 - Currently diagnosed and/or treated Obstructive Sleep Apnea, Restless Legs Syndrome, parasomnia - Congestive heart failure, by exam or Beta natriuretic peptide (BNP)> 30 pmol/L - Chronic kidney disease, stage III-V (eGFR<50) - >14 alcohol drinks per week

Study Design


Intervention

Behavioral:
Brief behavioral treatment of insomnia (BBTI)
The BBTI consists of a 45- to 60-minute individual intervention session followed by a 30-minute follow-up session 2 weeks later and 20-minute telephone calls after 1 and 3 weeks. The brief behavioral treatment component will focus on four behaviors that promote sleep through homeostatic, circadian, or association mechanisms. 50 These four interventions are simple to conceptualize and implement, and constitute the core of efficacious multi-modal behavioral treatments for insomnia.
Information-only control (IC)
The IC condition is intended to emulate the behavioral treatment information generally to available patients. It includes instructions to review hand out on healthy sleep practices. We will also use patient education videos on insomnia developed locally and widely used in clinical research. The content of these videos overlap substantially with BBTI but without individualized behavioral instructions. Two weeks later, IC participants will receive a 10-minute follow-up telephone call to encourage continued participation. Participants will be referred to the brochures for specific sleep-related questions.

Locations

Country Name City State
United States University of Pittsburgh Pittsburgh Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
University of Pittsburgh National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Nocturnal Polyuria Index Nocturnal Polyuria Index (NPI) is the percentage of 24-hour urine production excreted at night. It is measured using 3-day bladder diary that participants will complete pre- and post-intervention in which the participants document the time and volume of each void during the day and night for 3 days. NPI is calculated using a) nocturnal urine volume (determined by adding the volume of all voids between the times marked in the bladder diary as going to bed with the intent of sleeping and the first awakening to void. The first void after waking is included in the nighttime urine volume), and b) 24-hour urine volume. NPI is calculated as: nocturnal urine volume /24-hour urine volume change from baseline nocturnal polyuria index at 4 weeks
Secondary Change in Nocturia Nocturia=number of awakenings to void each night change from baseline nocturia episodes each night at 4 weeks
Secondary Change in Duration of Uninterrupted Sleep Duration of uninterrupted sleep is the first uninterrupted sleep period before first awakening to void Change from baseline duration of uninterrupted sleep at 4 weeks
See also
  Status Clinical Trial Phase
Completed NCT03623880 - Enhancing Behavioral Treatment for Women With Pelvic Floor Disorders N/A
Completed NCT02904759 - Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Male Subjects Phase 3
Completed NCT02905682 - Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Female Subjects Phase 3
Completed NCT02835846 - Investigation of the Effect of the Female Urinary Microbiome on Incontinence Phase 4
Completed NCT01684800 - Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult Women Phase 2
Completed NCT01694498 - Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult Men Phase 2
Completed NCT01520948 - Behavioral Therapy to Treat Urinary Symptoms in Parkinson Disease Phase 3
Completed NCT01222598 - A Study of Minirin Melt in Patients With Nocturia N/A
Recruiting NCT04305743 - Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A Phase 4
Completed NCT01486706 - Efficacy and Safety of Gabapentin in Treating Overactive Bladder Phase 2/Phase 3
Completed NCT04528784 - Feasibility Study of Transcutaneous Tibial Nerve Stimulation for Urinary Symptoms in People With Multiple Sclerosis N/A
Recruiting NCT05874375 - UCon Treatment of Overactive Bladder (OAB) in Males N/A
Completed NCT01223937 - Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients Phase 3
Withdrawn NCT01018225 - Exploratory Study Evaluating the Effects of Darifenacin on Nocturia, Sleep and Daytime Wakefulness Phase 4
Completed NCT05222477 - Abdominal Muscle Exercises on Nocturia and Sleep Quality in Women With Type 2 Diabetes N/A
Withdrawn NCT02961114 - Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy Phase 1/Phase 2
Completed NCT02440841 - Study in Healthy Male Subjects to Evaluate the Effect of Itraconazole and Rifampicin on the PK of Fedovapagon Phase 1
Completed NCT02068560 - The Effect of Gender on Antidiuresis - Evaluated by Graded Low Dose Desmopressin Infusion N/A
Completed NCT01357356 - Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia Phase 2/Phase 3
Completed NCT02151253 - Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia Phase 2/Phase 3